These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30055340)

  • 21. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.
    King WM; Ruttencutter R; Nagaraja HN; Matkovic V; Landoll J; Hoyle C; Mendell JR; Kissel JT
    Neurology; 2007 May; 68(19):1607-13. PubMed ID: 17485648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intermittent PTH treatment improves bone and muscle in glucocorticoid treated Mdx mice: A model of Duchenne Muscular Dystrophy.
    Yoon SH; Grynpas M; Mitchell J
    Bone; 2019 Apr; 121():232-242. PubMed ID: 30716510
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bone Mineral Density Assessment by Quantitative Computed Tomography in Glucocorticoid-Treated Boys With Duchenne Muscular Dystrophy: A Linear Mixed-Effects Modeling Approach.
    Liu C; Yang DD; Zhang L; Lei XG; Jia FL; Liao Y; Chen XJ; Ning G; Luo W; Qu HB
    Front Endocrinol (Lausanne); 2022; 13():860413. PubMed ID: 35399923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy.
    Zacharin M; Lim A; Gryllakis J; Siafarikas A; Jefferies C; Briody J; Heather N; Pitkin J; Emmanuel J; Lee KJ; Wang X; Simm PJ; Munns CF
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2328-2342. PubMed ID: 33954789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermittent versus daily regimen of prednisolone in ambulatory boys with Duchenne muscular dystrophy: A randomized, open-label trial.
    Kochar GS; Sondhi V; Kabra SK; Yadav SL; Dwivedi SN; Gulati S
    Muscle Nerve; 2022 Jan; 65(1):60-66. PubMed ID: 34617309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced bone mineral density in adolescents with Duchenne Muscular Dystrophy (DMD) and scoliosis.
    Tsaknakis K; Jäckle K; Lüders KA; Lorenz HM; Braunschweig L; Hell AK
    Osteoporos Int; 2022 Sep; 33(9):2011-2018. PubMed ID: 35583603
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low bone mineral density and decreased bone turnover in Duchenne muscular dystrophy.
    Söderpalm AC; Magnusson P; Ahlander AC; Karlsson J; Kroksmark AK; Tulinius M; Swolin-Eide D
    Neuromuscul Disord; 2007 Dec; 17(11-12):919-28. PubMed ID: 17627820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
    Sbrocchi AM; Rauch F; Jacob P; McCormick A; McMillan HJ; Matzinger MA; Ward LM
    Osteoporos Int; 2012 Nov; 23(11):2703-11. PubMed ID: 22297733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Factors Associated With Early Motor Function Trajectories in DMD After Glucocorticoid Initiation: Post Hoc Analysis of the FOR-DMD Trial.
    Schiava M; McDermott MP; Broomfield J; Abrams KR; Mayhew AG; McDonald CM; Martens WB; Gregory SJ; Griggs RC; Guglieri M;
    Neurology; 2024 May; 102(10):e209206. PubMed ID: 38710006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth, pubertal development, and skeletal health in boys with Duchenne Muscular Dystrophy.
    Ward LM; Weber DR
    Curr Opin Endocrinol Diabetes Obes; 2019 Feb; 26(1):39-48. PubMed ID: 30507696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
    JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regional changes in bone area and bone mineral content in boys with duchenne muscular dystrophy receiving corticosteroid therapy.
    Crabtree NJ; Roper H; McMurchie H; Shaw NJ
    J Pediatr; 2010 Mar; 156(3):450-5. PubMed ID: 19880140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histomorphometry and Bone Matrix Mineralization Before and After Bisphosphonate Treatment in Boys With Duchenne Muscular Dystrophy: A Paired Transiliac Biopsy Study.
    Misof BM; Roschger P; McMillan HJ; Ma J; Klaushofer K; Rauch F; Ward LM
    J Bone Miner Res; 2016 May; 31(5):1060-9. PubMed ID: 26615086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy.
    Nasomyont N; Keefe C; Tian C; Hornung L; Khoury J; Tilden JC; Hochwalt P; Jackson E; Rybalsky I; Wong BL; Rutter MM
    Osteoporos Int; 2020 Dec; 31(12):2449-2459. PubMed ID: 32676823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone mineral density and fractures in boys with Duchenne muscular dystrophy.
    Larson CM; Henderson RC
    J Pediatr Orthop; 2000; 20(1):71-4. PubMed ID: 10641693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone mineral density and bone metabolism in Duchenne muscular dystrophy.
    Bianchi ML; Mazzanti A; Galbiati E; Saraifoger S; Dubini A; Cornelio F; Morandi L
    Osteoporos Int; 2003 Sep; 14(9):761-7. PubMed ID: 12897980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fracture risk and impact in boys with Duchenne muscular dystrophy: A retrospective cohort study.
    Liaw J; Billich N; Carroll K; Adams J; Ryan MM; Yiu EM; Zacharin M; Simm P; Davidson ZE
    Muscle Nerve; 2023 Jun; 67(6):489-496. PubMed ID: 36478256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
    Tian C; Wong BL; Hornung L; Khoury JC; Rybalsky I; Shellenbarger KC; Rutter MM
    Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.